Franklin Street Advisors Inc. NC lifted its holdings in shares of Advaxis, Inc. (NASDAQ:ADXS) by 117.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 129,800 shares of the biotechnology company’s stock after acquiring an additional 70,000 shares during the period. Franklin Street Advisors Inc. NC’s holdings in Advaxis were worth $369,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of ADXS. Voya Investment Management LLC grew its position in Advaxis by 20.3% in the 2nd quarter. Voya Investment Management LLC now owns 17,612 shares of the biotechnology company’s stock worth $114,000 after purchasing an additional 2,975 shares in the last quarter. PNC Financial Services Group Inc. grew its position in Advaxis by 18.2% in the 2nd quarter. PNC Financial Services Group Inc. now owns 26,000 shares of the biotechnology company’s stock worth $168,000 after purchasing an additional 4,000 shares in the last quarter. Stonebridge Capital Management Inc. grew its position in Advaxis by 88.7% in the 3rd quarter. Stonebridge Capital Management Inc. now owns 42,650 shares of the biotechnology company’s stock worth $179,000 after purchasing an additional 20,045 shares in the last quarter. State of Wisconsin Investment Board bought a new stake in Advaxis in the 2nd quarter worth about $201,000. Finally, The Manufacturers Life Insurance Company grew its position in Advaxis by 10.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 31,431 shares of the biotechnology company’s stock worth $204,000 after purchasing an additional 2,969 shares in the last quarter. 41.65% of the stock is owned by institutional investors.

Shares of Advaxis, Inc. (NASDAQ:ADXS) opened at $2.92 on Thursday. Advaxis, Inc. has a 52-week low of $2.71 and a 52-week high of $10.06. The stock has a market cap of $119.91, a PE ratio of -1.27 and a beta of 1.91.

Advaxis (NASDAQ:ADXS) last issued its quarterly earnings data on Wednesday, December 20th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.55) by ($0.02). Advaxis had a negative return on equity of 114.00% and a negative net margin of 776.63%. The firm had revenue of $1.76 million during the quarter, compared to the consensus estimate of $3.05 million. equities analysts predict that Advaxis, Inc. will post -2.36 EPS for the current year.

A number of equities research analysts have issued reports on the stock. ValuEngine downgraded shares of Advaxis from a “sell” rating to a “strong sell” rating in a research report on Tuesday, October 3rd. Cantor Fitzgerald set a $19.00 price objective on shares of Advaxis and gave the stock a “buy” rating in a research report on Thursday, December 28th. Finally, HC Wainwright set a $23.00 price objective on shares of Advaxis and gave the stock a “buy” rating in a research report on Wednesday, December 27th.

In other Advaxis news, CFO Sara Bonstein sold 12,734 shares of the business’s stock in a transaction dated Thursday, November 2nd. The shares were sold at an average price of $3.19, for a total value of $40,621.46. Following the transaction, the chief financial officer now directly owns 244,504 shares in the company, valued at $779,967.76. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Robert Petit sold 12,625 shares of the business’s stock in a transaction dated Thursday, November 2nd. The shares were sold at an average price of $3.19, for a total transaction of $40,273.75. Following the completion of the transaction, the insider now owns 237,265 shares in the company, valued at $756,875.35. The disclosure for this sale can be found here. Over the last quarter, insiders sold 38,192 shares of company stock worth $122,615. Corporate insiders own 7.21% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This news story was published by Watch List News and is the property of of Watch List News. If you are viewing this news story on another website, it was illegally copied and republished in violation of U.S. & international copyright & trademark laws. The original version of this news story can be read at https://www.watchlistnews.com/franklin-street-advisors-inc-nc-acquires-70000-shares-of-advaxis-inc-adxs/1802454.html.

Advaxis Profile

Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.

Want to see what other hedge funds are holding ADXS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Advaxis, Inc. (NASDAQ:ADXS).

Institutional Ownership by Quarter for Advaxis (NASDAQ:ADXS)

Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.